For research use only. Not for use in humans.

Mogamulizumab (Anti-CCR4 / CD194)

Synonyms: KW-0761 Cat.No.A2568 Purity:99%

Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanised recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumour cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukaemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD.

Quality Control

Batch: A256801 Purity: 99% Protein concentration: 6.86mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Specificity

Name	Citation	CCR
Adaptavir (DAPTA)	3	+++

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanised recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumour cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukaemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1159266-37-1
Molecular Weight	144.12 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.